Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Jurnal Ilmu Farmasi dan Farmasi Klinik (Journal of Pharmaceutical Science and Clinical Pharmacy) JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)
Tri Murti Andayani
Fakultas Farmasi, Universitas Gadjah Mada, Yogyakarta
Health Professions Medicine & Pharmacology Public Health

Published : 6 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 6 Documents
Search

 1 
COST ANALYSIS OF CERVICAL CANCER MEDICAL TREATMENT AS A CONSIDERATION IN DETERMINING THE HEALTH COSTING DUE TO INA-DRGs AT RSUD Dr. MOEWARDI Devi Oktaviani; Iwan Dwiprahasto; Tri Murti Andayani
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Vol 2, No 1
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jmpf.59

Abstract

The implementation of INA-DRGs system for the third-class patients of Jamkesmas (Public Health Insurance Program) in hospital is expectedly able to increase the access and the health service quality for the poor and underprivileged people in effectively and efficiently realizing the optimal health service. This research was aimed to obtain the average cost of medical treatment of cervical cancer and also learn the compatibility between cost of medical treatment of cervical cancer in RSUD Dr. Moewardi and the constancy of INA-DRGs based health financing. This was a descriptive research under the perspective of hospital. Data was collected retrospectively by investigating the medical record document of patients with cervical cancer and the data of the medical treatment cost of patients. The research subject was cervical cancer case with the third-class patients of JAMKESMAS in RSUD Dr. Moewardi in the period of January-July 2010 that was in line with the inclusion criteria. Further, the data analysis was done by cross tab with Chi Square test and by comparing the average cost and ALOS (Average length of stay) through the constancy of INA-DRG. The Chi Square Test shows a correlation between LOS, patient factor (the number of parities), and disease factors (co-morbidity and severity level) with the health care cost for cervical cancer in RSUD. Dr. Moewardi. The health care average cost of cervical cancer based on the tariff of RSUD Dr. Moewardi for the severity level I included: IDR2.893.243 for surgery, IDR3.313.342 for chemotherapy, IDR3.988.027 for radiotherapy and IDR10.039.072 for radical hysterectomy. Meanwhile, in the severity level II, it included IDR5.885.859 for surgery, IDR4.474.084 for chemotherapy. In the severity level III, it includes IDR13.347.209 for radical hysterectomy. The ALOS was longer compared to ALOS of INA-DRG except in the severity level III. This then gives an effect on the health care cost for cervical cancer that in general was higher than the tariff of INA-DRG. In conclusion, implementation of INA-DRG for the treatment of cervical cancer in patients of JAMKESMAS in RSUD Dr. Moewardi was in efficient.Keywords: INA-DRG, cervical cancer, JAMKESMAS
EVALUASI TERAPI ADJUVAN DAN KEJADIAN RELAPS PADA PASIEN PREMENOPAUSAL EARLY BREAST CANCER DI RSUP DR. SARDJITO YOGYAKARTA Fef Rukminingsih; Tri Murti Andayani; Fita Rahmawati; Kartika Widayati
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Vol 7, No 1
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jmpf.364

Abstract

Terapi adjuvan pada pasien early breast cancer (EBC) bertujuan untuk meningkatkan disease free survival, menurunkan risiko relaps dan menurunkan angka kematian. Tetapi pada kenyataannya masih sering dijumpai, pasien EBC yang telah mendapat terapi adjuvan mengalami relaps. Kejadian relaps sering dihubungkan dengan meningkatnya risiko kematian tanpa memperhatikan jenis pengobatan. Tujuan penelitian ini adalah mengetahui angka kejadian relaps pada pasien premenopausal EBC yang telah mendapatkan terapi adjuvan di RSUP dr. Sardjito Yogyakarta. Penelitian ini merupakan penelitian deskriptif observasional dengan desain cross sectional study menggunakan data retrospektif yang diperoleh dari data rekam medik pasien premenopausal EBC di Poliklinik Kanker Terpadu “Tulip” RSUP dr. Sardjito Yogyakarta yang telah mengalami tindakan pembedahan pada tahun 2010-2013, bersifat hormon responsif dan HER-2 negatif, mendapatkan terapi adjuvan, perempuan dengan umur 18-60 tahun dan  riwayat pemeriksaan sampai bulan Desember 2016. Pasien akan di eksklusi bila mempunyai penyakit penyerta. Dari 30 pasien diketahui sebanyak 46,67% berumur 41-50 tahun, sebanyak 63,33% menunjukkan ekspresi ER-PR positif, sebanyak 93,34% merupakan invasive ductal carcinoma (IDC). Semua pasien mendapatkan terapi adjuvan kemoterapi menggunakan regimen kombinasi dan semua pasien mendapatkan terapi endokrin berupa tamoksifen. Relaps terjadi pada 11 pasien (36,67%) dan kejadian relaps paling banyak adalah metastasis tulang yaitu pada 8 pasien (26,67%).
PERBANDINGAN PILL BOX DAN MEDICATION CHART DALAM MENINGKATKAN KEPATUHAN DAN OUTCOME KLINIK GERIATRI KOTA BATAM Suci Fitriani Sammulia; Fita Rahmawati; Tri Murti Andayani
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Vol 6, No 4
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jmpf.358

Abstract

Banyaknya obat yang dikonsumsi oleh pasien geriatri dengan penyakit kronis meningkatkan penurunan kepatuhan. Ada beberapa cara dalam meningkatkan kepatuhan diantaranya dengan menggunakan Pill box dan Medication reminder chart. Penelitian ini bertujuan untuk mengetahui perbandingan efektifitas penggunaan Pill box dengan Medication reminder chart dalam meningkatkan kepatuhan pasien geriatri dengan hipertensi di Kota Batam. Rancangan Penelitian ini adalah studi experimental; Randomized Controlled Trial dengan desain penelitian pre test dan post test control group. Pengambilan sampel pada penelitian ini dilakukan dengan teknik random alokasi sampling. Pasien akan dikelompokkan menjadi dua kelompok subjek yang berbeda, yaitu kelompok yang mendapat intervensi berupa Pill box dan Medication reminder chart. Data dikumpulkan secara prospektif sesuai dengan kriteria inklusi padap asien geritri rawat jalan, dengan diagnosa penyakit hipertensi di dua rumah sakit Kota Batam, penelitian dilakukan pada bulan Januari sampai April 2016. Pengukuran tingkat kepatuhan menggunakan kuesioner MMAS-8 dan pill count dan outcome klinik pasien diukur dengan melihat tekanan darah sistolik dan diastolik yang disesuaikan dengan diagnosa dokter yang tertera di rekam medik. Pengukuran dilakukan sebelum dan sesudah perlakuan. Data dianalisis secara statistik menggunakan deskripitif, uji bivariat. Hasil penelitian ini menunjukkan bahwa Pill box dapat meningkatkan kepatuhan (P=0,000) dan menurunkan tekanan darah sistolik dan diastolik secara signifikan (P=0,000 dan P=0,002), sedangkan pada Medication reminder chart hanya efektif dalam meningkatkan kepatuhan (P=0,000). Terdapat perbedaan yang signifikan antara Pill box dan Medication reminder chart dalam meningkatkan kepatuhan (P=0,008) dan pada penurunan tekanan darah sistolik dan diastolik (P=0,006 dan P= 0,016).
COST ANALYSIS OF THERAPY FOR BREAST CANCER PATIENTS WITH HORMONE THERAPY Vina Purnamasari; Tri Murti Andayani; Achmad Fudholi
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Vol 5, No 1
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jmpf.31

Abstract

One of the breast cancer management is done by hormone therapy. This study aimed to determine the main cost component of therapy, the cost of therapy both in outpatient and inpatient, and also the influence of patient characteristics, factor of therapy, and type of hormone therapy on breast cancer treatment costs at RSUP dr Wahidin Sudirohusodo. The research method was an analitic observational study from hospital perspective. The subjects were outpatient and inpatient with breast cancer in the period January-June 2014 at RSUP dr. Wahidin Sudirohusodo who met the inclusion criteria. The data was collected retrospectively which extracted from medical records and the treatment costdata from breast cancer patients. The data was analyzed by calculating the prevalence of breast cancer patients given hormone therapy, major components of costs, and expenses for each component, both for therapy outpatient or inpatient. The results showed that breast cancer patient which included in inclusion criteria were 105 patient. The range cost for inpatient surgerywas Rp 5.436.756 - Rp 5.646.678 with the largest cost component was the medical substance after use (BHP) which included in the cost of medical action 28,6%. The cost range for inpatient chemotheraphy was Rp 2.546.166 - Rp. 6.823.821 with the largest cost component was the cost of drugs namely 83,5%. The cost range for outpatient was  Rp 1.538.750 - Rp 4.202.935 with the largest cost component was the cost of drugs namely 63,57%. Patient characteristics that influenced the cost of breast cancer were stage (p = 0,001), medical action (p = 0.001), and cycles of therapy (p = 0,027). In addition, the type of hormone therapy also affects the cost of breast cancer (p = 0,047).Keywords: breast cancer, hormone therapy, cost of therapy
COST ANALYSIS OF DIABETES MELLITUS Elny Fitri; Tri Murti Andayani; Endang Suparniati
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Vol 5, No 1
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jmpf.30

Abstract

The high prevalence and complication of diabetes mellitus, as a chronic non-communicable disease, result a significant economicburden for the healthcare cost. This study aimed to calculate the total cost of illness, the effect of age, complication, the period andclass of inpatient on the real cost, the differences between the total of the real cost compared to the standard treatment cost of INACBGs for diabetic patients in the period of January until June 2014 in Dr. Sardjito Hospital, Yogyakarta. This research was a non-experimental analytic using retrospective approach. Research was conducted based on the hospital prespective by calculating the directmedical costs using a bottom-up approach. The samples included 1.396 patients with 1.935 episodes of care. The independentvariables included age, complications, length of hospitalization and treatment class, while the dependent variable was the real cost.The data was analyzed using the multiple regression statistic analysis. The result showed that the total cost of illness of diabetesmellitus was IDR 15.248.582,600. The multiple linear regression analysis showed that the complication and length of stay were the most influencing factors to the real costs of diabetic outpatients and inpatients. There was a difference between the realtotal cost and the standard treatment cost of INA-CBGs foroutpatient and inpatient with type 1 diabetic and also inpatient with type 2diabetes around IDR 46.511.644, IDR 100.647.901, and IDR 186.542.144 respectively  in which the real total cost was lower than the INA CBG’s standard.Moreover, there was a difference in the real cost of outpatients with type 2 diabetic around IDR Rp -196.698.235 that higher than INA-CBG’s standard. Keywords: cost of illness, diabetes mellitus, INA-CBGs
HUBUNGAN GENOTIPE rs 1042713 (Arg16Gly) DENGAN EFEKTIVITAS 2-AGONIS PADA PENDERITA ASMA Sri Haryanti; Zullies Ikawati; Mustofa Mustofa; Tri Murti Andayani
Jurnal Ilmu Farmasi dan Farmasi Klinik Vol 18, No 01 (2021): Jurnal Ilmu Farmasi & Farmasi Klinik
Publisher : Universitas Wahid Hasyim Semarang

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (268.248 KB) | DOI: 10.31942/jiffk.v18i01.4894

Abstract

ABSTRACT To produce an effect, the agonist drug 2 will bind to the ADRB2 receptor. The effect of agonist 2 shows variation between individuals due to the presence of encoding gene polymorphisms. There are 80 ADRB2 polymorphisms, including Arg16Gly in amino acids 16. The innate ADRB2 genotype is called wildtype, whereas mutated ones is called mutant. The purpose of this study was to determine whether there was a relationship between genotype rs 1042713 (Arg16Gly) and the effectiveness of β2-agonist drugs in asthma sufferers. This study was an observational study with a cross sectional design and prospective data collection. Examination of the presence of gene polymorphisms and assessment of effe A total of 101 asthma patients who met the inclusion criteria were sorted by genome type by pharmacogenomic examination uses the Asthma Control Test (ACT) questionnaire. The results of the statistical test with chi square to determine the relationship of genome type and asthma control obtained p value 0.131. The comparison of the effectiveness of the wildtype genome is more effective than the mutant of 1.887x, and heterozygote is more effective 1,667x greater than the mutant. There is no significant relation between genotypes rs 1042713 (Arg16Gly) with effectiveness, but the possibility of clinical effectiveness is different. Keywords: Asthma, β2-agonist, ADRB2, genotype, effectiveness.
Co-Authors Achmad Fudholi Devi Oktaviani Elny Fitri Endang Suparniati Fef Rukminingsih Fita Rahmawati Iwan Dwiprahasto Kartika Widayati Taroeno Hariadi Mustofa Mustofa Rahmawati, Fita Sri Haryanti Suci Fitriani Sammulia Vina Purnamasari